LTA4H Activators

LTA4H Activators are a diverse group of chemical compounds that indirectly increase the enzymatic activity of LTA4H through modulation of the leukotriene synthesis pathway. Bestatin, for instance, acts upstream by inhibiting aminopeptidases, which may lead to a higher concentration of LTA4 available for conversion by LTA4H into the potent inflammatory mediator LTB4, thereby enhancing LTA4H activity. Similarly, Zileuton and MK-886, by selectively inhibiting 5-lipoxygenase and FLAP respectively, decrease the competition for arachidonic acid metabolites, indirectly leading to a relative increase in LTA4H substrate availability. This could result in an enhanced production of LTB4, despite their primary roles as inhibitors. Compounds like GSK2190915 and A-64077 further support this mechanism by also targeting FLAP, suggesting a common strategy among several activators to increase LTA4 substrate availability for LTA4H.

On the other hand, leukotriene B4 receptor antagonists like LY255283 and CP-105696 indirectly promote LTA4H activity by creating a feedback demand for LTB4, which in turn may lead to increased enzymatic action of LTA4H. ONO-4057 follows a similar rationale, where its inhibitory action on leukotriene B4 could potentially spur an increase in LTA4H-mediated synthesis of LTB4 to compensate for the inhibited signaling. These activators, despite their varied primary mechanisms of action, collectively contribute to the enhancement of LTA4H's role in producing inflammatory leukotrienes without any direct activation or upregulation of the enzyme's expression.